Miglustat as a Treatment for Adults with Tangier Disease Neuropathy: The MUSTANG N-of-1 Trial with 21 months Clinical Observation

医学 丹吉尔病 神经学 内科学 临床试验 儿科 疾病 临床疾病 外科 加药 流行病学 芬戈莫德 药物治疗
作者
Andrew Cook,Beth L. Stuart,Antonio F. Ochoa-Ferraro,Nicola Condon,Megan M. Lawrence,Fran Webley,Kerri‐Lee Wallom,Claire Forbes,Vishy Veeranna,Subadra Wanninayake,Tom Oliver,Nicholas Davies,Charlotte Dawson,Frances M. Platt,Tarekegn Geberhiwot
出处
期刊:Neurology and Therapy [Adis, Springer Healthcare]
卷期号:15 (1): 447-456
标识
DOI:10.1007/s40120-025-00843-6
摘要

IMPORTANCE: Tangier disease (TD) is an ultra-rare disease, characterised by progressive peripheral neuropathy with no established treatment. OBJECTIVES: To determine whether miglustat improved the clinical status of a single patient with TD, and to investigate the possible mechanisms of miglustat in this patient. DESIGN, SETTING, AND PARTICIPANTS: An n-of-1 ABAB study, alternating on and off treatment for 6-month periods, total study duration of 2 years with an additional compassionate-access period of 21 months. EXPOSURE: Miglustat, an orphan drug licenced to treat Gaucher disease and Niemann-Pick disease, was repurposed. MAIN OUTCOMES AND MEASURES: The study was designed with two co-primary endpoints: (a) time taken to complete the nine-hole peg test (fine motor control and finger dexterity), and (b) hand strength: grip and three-point pinch strength tests. Secondary endpoints were quality-of-life measures and biomarkers. RESULTS: A 21-year-old (at baseline) left-handed male patient with TD, diagnosed at the age of 6 months, and disabling neuropathy was included in the study. Over 2 years, there was a small signal in our clinical measures that the drug may be beneficial. Compared with the 2 years prior to treatment, the patient had no relapse of neuropathy during his study period and further extension. During the 21-month treatment extension, he showed considerable improvement on primary endpoints. Biomarkers changed as expected based on the mechanism of action of miglustat. Nerve conduction studies showed a mild benefit. Importantly, the patient's reported experience suggested a meaningful benefit from miglustat. CONCLUSIONS AND RELEVANCE: Miglustat may be used to treat neurological complications of TD. This study showed that an n-of-1 study to inform a policy decision is practical and may offer hope to patients with rare diseases. TRIAL REGISTRATION: ClinicalTrials.gov Identifier: ISRCTN17945917. Registration date: 07/06/2021; 'retrospectively registered'.
最长约 10秒,即可获得该文献文件

科研通智能强力驱动
Strongly Powered by AbleSci AI
科研通是完全免费的文献互助平台,具备全网最快的应助速度,最高的求助完成率。 对每一个文献求助,科研通都将尽心尽力,给求助人一个满意的交代。
实时播报
彭于彦祖的应助被jc哥采纳,获得50
刚刚
刚刚
小二郎的应助被结实初兰采纳,获得10
1秒前
烧鸭饭发布了新的文献求助10
2秒前
三千弱水为君饮完成签到,获得积分10
2秒前
梅林渔夫发布了新的文献求助10
2秒前
Rainbow发布了新的文献求助10
2秒前
3秒前
不爱喝纯牛奶完成签到,获得积分10
3秒前
天天快乐的应助被迪迪张采纳,获得10
3秒前
3秒前
今后的应助被痞老板采纳,获得10
3秒前
3秒前
LV发布了新的文献求助10
4秒前
4秒前
Owen的应助被木子采纳,获得10
4秒前
诚心的志泽完成签到,获得积分10
4秒前
赵宇欣完成签到,获得积分10
5秒前
5秒前
文绿完成签到 ,获得积分10
5秒前
5秒前
甘甘甘甘完成签到,获得积分10
5秒前
挡挡完成签到,获得积分10
5秒前
5秒前
科研狗完成签到,获得积分10
6秒前
坦率帅哥完成签到 ,获得积分10
6秒前
6秒前
7秒前
优美绮琴完成签到,获得积分10
7秒前
king完成签到,获得积分10
7秒前
CodeCraft的应助被沉静土豆采纳,获得10
7秒前
努力的科研混子完成签到,获得积分10
7秒前
典雅的迎波完成签到,获得积分10
7秒前
min发布了新的文献求助10
7秒前
8秒前
躲进小楼完成签到,获得积分10
8秒前
8秒前
mx完成签到,获得积分10
8秒前
8秒前
9秒前
高分求助中
(应助此贴封号)【重要!!请各用户(尤其是新用户)详细阅读】【科研通的精品贴汇总】 10000
拉伸高分子熔体中缠结行为的模拟和小角中子散射研究 1700
The World Atlas of Wine 9th edition 1000
奈特基础组织学:配套组织病理学(第4版)(Netter's Essential Histology With Correlated Histopathology) 800
John McDowells Bildungstheorie 800
Social Psychology in the Real World 600
八旗制度の研究 600
热门求助领域 (近24小时)
化学 材料科学 医学 生物 纳米技术 计算机科学 工程类 有机化学 化学工程 生物化学 物理 复合材料 内科学 催化作用 光电子学 人工智能 细胞生物学 无机化学 物理化学 数学
热门帖子
关注 科研通微信公众号,转发送积分 8181072
求助须知:如何正确求助?哪些是违规求助? 9571092
关于积分的说明 21816478
捐赠科研通 7777477
什么是DOI,文献DOI怎么找? 3433418
关于科研通互助平台的介绍 2557638
邀请新用户注册赠送积分活动 2479460